NASDAQ:XFOR X4 Pharmaceuticals Q2 2024 Earnings Report $3.15 -0.15 (-4.55%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast X4 Pharmaceuticals EPS ResultsActual EPS$0.30Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AX4 Pharmaceuticals Revenue ResultsActual Revenue$3.43 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AX4 Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call DateThursday, August 8, 2024Conference Call Time8:30AM ETConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by X4 Pharmaceuticals Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 8, 2024 ShareLink copied to clipboard.There are 11 speakers on the call. Operator00:00:00Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Also, today's call is being recorded. It is now my pleasure to introduce your host, Mr. Operator00:00:29Dan Ferry from LifeSci Advisors. Dan, please go ahead. Speaker 100:00:33Thank you, operator, and good morning, everyone. Thank you for joining us today. Presenting on today's call will be Doctor. Paula Ragan, X4's President and CEO and the company's Chief Financial Officer, Adam Mostafa. Following prepared remarks, we will open up the call to your questions and will be joined by Chief Commercial Officer, Mark Baldry Chief Medical Officer, Doctor. Speaker 100:00:54Christophe Arbitt Engels Chief Operating Officer, Doctor. Mary DiBiase Chief Scientific Officer, Doctor. Art Tavares and Jose Juves, Head of Corporate and Patient Affairs. As a reminder, on today's call, the company will be making forward looking statements regarding regulatory and product development and commercialization plans as well as research activities and financial projections. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Speaker 100:01:26A description of these risks can be found in Exforge's most recent filings with the SEC, including this year's Form 10 ks, which was filed on March 21, 2024, and in the company's Form 10 Q for the 2nd quarter, which is expected to be filed later today. I'll now turn it over to Paula Ragan. Paula? Speaker 200:01:50Thanks so much, Dan, and welcome, everyone. I'll just start by saying what an incredible year we've had so far. Just a few weeks ago, we celebrated the 10th anniversary of X4. When we founded the company a decade ago, a small group of us had a vision to advance our lead asset, an orally active CXCR4 antagonist called maverixaphore to help those with rare diseases who have few to no treatment options. As you saw this past April, we were able to realize this vision receiving U. Speaker 200:02:20S. Approval of maverixophore branded as Zolrembe for the treatment of WIM syndrome, a rare primary immunodeficiency. The U. S. Launch of Zolrembe is now underway and our full commercial team is in place and when patients 12 years and older are now being treated with the only approved therapy targeting the underlying cause of their disease. Speaker 200:02:44Sales guidance on Zolremdi will come at a future point. However, today, I'd like to highlight our strong launch progress. Overall, we've been very pleased with the launch to date. Our launch meeting in early May was a great success where we completed the training and education of our field teams, enabling them to hit the ground running. We got product into our distribution channel very quickly and had our first patients on commercial drug within just a few weeks of product approval. Speaker 200:03:13Coordination with our specialty pharmacy Panther Rx Rare has gone smoothly and we've already received positive feedback on the patient support services provided through our X4 Connect and Nurse Educator programs. And very encouragingly, reimbursement decisions have been coming through quickly with almost all patients currently on therapy receiving reimbursement via prior authorizations and medical exceptions. Our commercial team is fully deployed across the U. S. Calling on key hematologists and immunologists. Speaker 200:03:47To date, there has been limited ability to establish centers of excellence for the WIM community. We knew this going in and therefore are continuing to execute on our disease awareness and education campaigns as well as leveraging our strong relationships with patient advocacy groups. We recently participated in the annual meeting of the Immune Deficiency Foundation or IDF where we engage with physicians, patients and advocates. And members of our team visited with the Jeffrey Modell Foundation in New York just a few weeks ago. Through all of these efforts, we have become better at engaging with the treating physicians, understanding physician and patient questions, and most importantly, building a community of interest around WIM syndrome across the U. Speaker 200:04:32S. We also continue to leverage the positive data from our pivotal Phase III trial in WIM that were published in April in Blood, the Journal of the American Society of Hematology. These and new data from the trial and its open label extension phase were presented at the Annual Meeting of the Clinical Immunological Society or CIS in early May. As we reported at the time, the CIS poster revealed that longer term treatment with ZolremD was associated with durable improvements in neutrophil and lymphocyte counts as well as reductions in annualized infection rates and that no new safety signals have been observed during the OLE phase of the trial with some participants treated for more than 2 years. We also made tremendous progress this past quarter in our development of MAVERICKZIPORE for those with chronic neutropenia, another rare immunodeficiency. Speaker 200:05:29At our investor event in late June, we presented positive interim clinical data from our ongoing Phase 2 clinical trial demonstrating that once daily oral mavrixophore was generally well tolerated and durably increased participants' absolute neutrophil counts or ANC both as a monotherapy and in combination with stable doses of injectable granulocyte colony stimulating factor or G CSF up to as long as 6 months. Importantly, 100% of evaluable participants who had completed the 6 month study as of the mid May cutoff date achieved target ANC increases of greater than 500 cells per microliter at months 36 on once daily MAVERICK-four as a monotherapy and in combination with stable TCSF dosing. In addition, participants on MAVERICKS-four monotherapy achieved mean ANC levels above the lower limit of normal for CN at 3 6 months. And MAVERICK's for monotherapy also durably increased AMC in participants with severe CN defined as ANCs less than 500 cells per microliter at baseline, achieving mean ANCs of 800 to 1000 cells per microliter, which is the A and C range targeted by experts for patients with severe CN. Feedback on these interim results from the physician community has been positive and we were pleased to see the durable impact of MAVERICK-four as a monotherapy and in combination with stable dose G CSF. Speaker 200:07:08These interim data support our strong belief that MAVERICKS-four may be able to address the needs of the CN patients and their physicians, specifically the desire for an oral treatment that does not carry short or long term dose related toxicities described with G CSF use and for an oral treatment that also increases ANC levels and lessens the risk and severity of infections whether used on its own or in combination with G CSF. We're now expecting present the full data from the Phase 2CN trial in November ahead of the American Society of Hematology or ASH meeting. This data set will include results from the group of participants receiving MAVERICK's support and those who are allowed to dose adjust G CSF from baseline. We've been asked what success looks like for these data that will be presented in November. The good news is we already know what success looks like from our WIM Phase 3 study and subsequent approval in the U. Speaker 200:08:08S. In that 52 week study, MAVERICK score meaningfully increased neutrophils and lymphocytes over a sustained period reducing infection rate, duration and severity. From the interim CN Phase II results we shared in June, we saw again that MAVERICK's IV as a monotherapy and in combination with G CSF can increase ANCs to levels expected to reduce infections. In November, we'll be looking to replicate what we saw in June across all participants in the MAVERICKS-four monotherapy and MAV plus stable dose G CSF groups who completed the 6 months of the trial. From the 3rd group, we'll be looking for data that supports physicians' ability to reduce G CSF dosing while on MAVERICK-four and maintain patients' ANCs at clinically meaningful levels. Speaker 200:08:59Finally, we'll be also looking for continued tolerability and safety of MAVERICKS-four as seen in all of our other clinical programs to date. In June, we also announced the initiation of our global pivotal Phase 3 clinical trial branded the FORWARD study evaluating the efficacy, safety and tolerability of oral once daily MAVERICK's 4 with and without stable doses of G CSF in people with congenital acquired primary autoimmune or idiopathic CN who are experiencing recurrent and or serious infections. The 52 week FORWARD trial is a randomized, double blinded, placebo controlled, multicenter study aiming to enroll 150 participants. The clinical operations team is in full swing opening up sites and we are on track to fully enroll the trial in mid-twenty 25. We believe that the interim Phase 2 CN data presented to date strongly support our decision to initiate the Phase 3 trial as well as its design. Speaker 200:10:03Importantly, we believe that the interim results derisk the Phase 3 trial given that the ANC increases seen in CN patients to date mirror those in our successfully completed for a WIM Phase 3 trial, where similar levels of ANC increases led to clinical benefit by reducing the frequency, duration and severity of infections. As we focus our efforts on the FORWARD CAND trial, we are also looking to maximize the global opportunity in WIMS syndrome. We expect an MAA submission to the European Medicines Agency for MAVERICK 4 and WIM syndrome by early 2025, while we also explore additional potential opportunities in geographies where we may be able to efficiently leverage our U. S. FDA approval. Speaker 200:10:50With that, I'll now turn it over to our CFO, Adam Asthafaa to review the Q2 financials. Adam? Speaker 300:10:58Thanks, Paula, and thanks to all of you for being on the call with us today. As we had previously discussed, upon FDA approval of XolRemd, we were awarded a Priority Review Voucher or PRV based on Maverick's 4 rare pediatric disease designation. We monetized this PRV very shortly after receipt and in May, we recognized a gain on the sale to a third party for $105,000,000 in cash. So as of the end of the Q2, ExCoR had $169,500,000 in cash, cash equivalents, restricted cash and short term marketable securities. We believe these funds are sufficient to support our company operations until late 2025. Speaker 300:11:42I want to note that this projected runway does not include potential future Zolram D revenue. For the 3 months ended June 30, we reported revenues of $600,000 and cost of revenue of 0 point $3,000,000 related to the sale of Zolremby. This cost of revenue includes approximately $200,000 of license costs, including sales based royalties and operational milestones capitalized as an intangible asset and amortized over the life of the underlying intellectual property. We would like to note that there was a small amount of inventory stocking at our specialty pharmacy during the quarter and this is reflected in the sales number. Research and development expenses were $20,900,000 for the 2nd quarter compared to $15,600,000 for the comparable period in 2023. Speaker 300:12:37R and D expenses for the Q2 of 2024 included $1,200,000 of non cash expense. Selling, general and administrative expenses were $13,300,000 for the Q2 of 2024. This compares to $10,200,000 for the comparable period in 2023. SG and A expenses for the Q2 also included $1,200,000 of non cash expense. Finally, we reported net income of $90,800,000 for the Q2 of 2024 compared to a net loss of $55,700,000 for the comparable period in 2023. Speaker 300:13:17Note that net income in the current period included the sale of PRV for $105,000,000 as well as a non cash gain of $20,200,000 related to the fair value remeasurement of the company's Class C warrant liability. I'll now turn it back to Paula for some concluding remarks. Speaker 200:13:38As you can see, all of these accomplishments mark a significant step forward for X4, now a fully integrated biopharmaceutical company. As we continue to explore additional uses for and maximize the global potential of MAVERICK's 4 for patients, we look forward to reporting on our sales, regulatory and clinical progress over the coming 6 to 12 months. We'll now open up the call for your questions. Operator? Operator00:14:05Thank you, Doctor. Reagan. We'll go first this morning to Kristin Kluska of Cantor. Speaker 400:14:23Hey, good morning, everybody, and congratulations on reaching 10 years. It's a great milestone and how better to celebrate with a drug approval this year. So first I wanted to ask how you believe physicians are going to measure success differently in a commercial setting versus the clinic for ZolremD? Will it be primarily on patient anecdotes, reports around infections or anything else to consider? Speaker 200:14:50Thanks, Kristen. I'll turn it over to Mark to give some perspectives on what they're hearing from the field. Speaker 500:14:56Yes. We're the launch is well underway, Kristen. And what's exciting is that we're hearing that physicians and patients been waiting for a treatment that targets the underlying cause of the disease. And so now we have the approval of Zolremdi. It's really opening up these conversations and allowing us to help physicians become aware of the disease, recognize the patients in their practice and then think about how they can help these patients with Zolremdi. Speaker 500:15:24We know from the market research that it's really the impact on infections that drives the value of Zolremdi for physicians, for patients and payers. So that's really what I think physicians will be looking for as they get more experience with the product. Speaker 400:15:42Thank you for that. And can you give us a sense of how partnership discussions ex U. S. Are going at this stage? And just curious, your press release noted some ways you're looking to maximize the value of meverx before beyond Wynd syndrome and CN. Speaker 400:15:57So curious as in these conversations this has come up with potential partners about ways that they can also potentially utilize this drug and other indications as well? Speaker 200:16:09Yes. So thanks, Kristen. I mean, when we currently think about the FDA approval, there are certain regions in the world that can leverage that existing approval. So there's some exploration there currently ongoing. Adam can comment more on the more strategic sides of potential collaborations. Speaker 300:16:27Yes. Thanks, Kristen. So certainly there is interest and we have discussions as Paul mentioned ongoing with potential partners. We'll certainly come back and update the market as appropriate if we're going to consummate a transaction. But I think given the recent approval and our recent positive cry neutropenia Phase 2 data, there's only growing interest in this area. Speaker 200:16:51Great. Thank you. Operator00:16:55Thank you. We go next now to Ted Tenthoff at Piper Sandler. Speaker 600:17:00Great. Thank you very much for taking my question. And yes, excited to see some revenues at the company that's and a lot of work has gone to get that first couple of 100 dollars, and I know it will grow from here. My question had to do with sort of characterizing the patients that are on drug. Can you give us a sense for how many patients are on drug? Speaker 600:17:21And anything about sort of the backlog? And if you're not able to give us direct patient numbers, maybe tell us sort of a little bit about the journey of patients that you're seeing as you sort of get them into commercial use of Zolremdi? Thank you. Speaker 200:17:41Thanks so much, Ted. So I think we won't be breaking down any details and continue to report on revenue. But I mean, we're overall extremely pleased with just the cascade of commitment that the company has made and then now we're experiencing the receipt of that commitment in the communities as we head out. But Mark can add some more color and kind of how they're seeing the journey from the diagnosis and education support all the way through patients on drug. Speaker 500:18:05Yes. And I think the first thing to remember, this is an ultra rare disease. And so the key here is to begin to really raise awareness both through the conversations we're having with physicians, our engagement with patient advocacy groups and also through our digital marketing campaigns because that's where we can get extended reach and we've refreshed our disease awareness campaign. We've also launched our branded Zolremdi digital campaigns. So we're really creating this kind of momentum around the conversations. Speaker 500:18:38And the patients as Paula mentioned on the call, all of the patients that were in the open label extension have been prescribed ZIL REMBI here in the U. S. And so from there we're just learning more and more about how the patients have been waiting for a treatment that targets their disease and they're now having those conversations with physicians. Speaker 600:19:01Great. That's really helpful. I appreciate the additional color. Operator00:19:08Thank you. We go next now to RK at H. C. Wainwright. Speaker 700:19:12Thank you. Good morning, Paula and Adam. Congratulations on the 10 years and also the launch. In terms of I know it's early stages of the launch, but when you go and attend these conferences such as the immunodeficiency conference, However, what is it that you're hearing from physicians and patients at this point in terms of getting ready to take to adopt the drug? And also have you learned anything else that needs to be looked at in terms of improving I'm not saying improving, getting that option to a better level from the get go. Speaker 200:20:10Thanks so much, RK. I think we're very pleased with kind of the cascade of thinking and development. And certainly what we're hearing and Mark will add to this is, number 1, they're excited about a targeted therapy and I'll even add the oral targeted therapy. It's been a field of injectable treatments with varying degrees of study and rigor. Our Phase 3 was phenomenally successful showing infection burden reduction across rate severity and duration. Speaker 200:20:39So that is a great story to begin with and a great data set to share. And then in terms of the clinicians, of course, they're all on their own journey even understanding the disease and then learning about the benefits of ZolremD. But I'll turn it over to Mark to add some color to that as well. Speaker 500:20:55Yes, exactly. I think it's really now that we have an approved product, it's really energized physicians to go back and really look in their practice for these patients who before now have really had no treatment available for their disease. And so now we've actually given them a reason to go back, look for these patients, make the diagnosis and then have a conversation with the patient about Zolremdi. Speaker 700:21:19Fantastic. And then for the SCN indication, so between now and if there is an interim analysis for the FORWARD study, is there any other data that will be presented so that we can understand how this program is moving forward? Speaker 200:21:49Sure. So, as we shared today, we'll be giving the full Phase 2 data set in November of this year. So, of course, we were extremely pleased with the data set already, but it was interim. So we've already seen durable responses of the drug as monotherapy and then sustained and durable responses in addition to stable G CSF. So the final puzzle piece is just exploring, in what circumstances G can get reduced. Speaker 200:22:14So that full data set will come in November, which is going to be certainly well timed, just before ASH, we'll be at the ASH meeting to help support the CN community and also get the word further out on our trial enrollment. So it's an excellent timing perspective and then we'll look forward as appropriate to giving updates on how the whole study is going, but certainly that will be a 2025 update. Speaker 700:22:40Perfect. Thank you very much for taking my questions, Paul. Speaker 200:22:45Thanks, RK. Operator00:22:48We'll take our next question now from Lia Can of Brookline Capital Markets. Speaker 800:22:53Good morning. I have a financial question. So Adam, could you help us with the number of fully diluted shares at the end of the quarter, including the prefunded warrants? Speaker 700:23:07Sure. Speaker 300:23:08Thanks. So there's about 167,000,000 basic shares, regular shares outstanding, dollars 33,000,000 prefunded warrants. So $200,000,000 of share equivalents, if you will. And then there are $75,000,000 warrants that are cash only. Those are divided into 2 tranches, $130,000,000 tranche, dollars 145,000,000 tranche. Speaker 300:23:35So overall, dollars 275,000,000 in fully diluted shares. There's some historical warrants you'll see later today in our 10 Q that are significantly out of the money and are typically not included, but that accounts for a small piece. Speaker 800:23:49Thank you so much. Most helpful. Operator00:23:56We go next now to Stephen Willey at Stifel. Speaker 900:24:02Yes, good morning. Thank you for taking the questions. Speaker 500:24:06Could you maybe just talk Speaker 900:24:08a little bit about and again, I understand that it's early, but the kinetics of the reimbursement process, I know the paperwork that is required sometimes for these higher price rare disease drugs can be a somewhat lengthy process. And just curious if you have an early read just based on the limited experience thus far as to what that process might look like from just a timing perspective? Speaker 200:24:39Sure, Steve. I mean, I'll turn it over to Mark. I think classic ultra rare disease typically has barriers that a lot of these insurance companies naturally provide given the magnitude of the drug and its options for patients. But the good news is I think we've had an very experienced team well ahead of this. So I'll turn it over to Mark to give some insights there. Speaker 500:25:00Yes. Thanks, Paul. Hi, Steve. Yes, as Paul mentioned during the call, payers are using their standard methods for new drugs. And so, they're looking at PAs and exceptions process, But these are working quite smoothly and patients have been able to access Oremdi. Speaker 500:25:17Of course, we also have our full suite of patient service programs through our X4 Connect, which is our patient hub. And this ensures that patients are quickly get quick access to the product while we work through the reimbursement. But it's good to see the process working smoothly. Speaker 900:25:39Okay. That's helpful. And maybe a guidance question, not one related to actual sales, but just curious how you're thinking about communicating enrollment progress in the Phase III FORWARD trial going forward? Should we expect updates in conjunction with certain milestones hit like 50%? Or is this just going to be kind of a moving target and we'll hear about it when we hear about it? Speaker 200:26:14Yes. Thanks, Steve. I think we'll always aim to communicate meaningful progress. Of course, we don't want to make any commitments just because it's a 2025 target and it's almost a year away at this point. However, certainly as we get confidence under our belt here, we'll be able to provide some more specifics. Speaker 200:26:33But again, I would say that's a 2025 zone to share. Speaker 900:26:40Okay. And then maybe just another financial question for Adam. SG and A just looks to be down about 25% sequentially, which I guess I wouldn't have been anticipated in the context of undertaking a launch. So can you just remind us if there's anything either unique to the 1 quarter number or this quarter number that impacts that SG and A line item? Thank you. Speaker 300:27:12Sure. Thanks, Steve. Yes, so this second quarter number is probably more representative of a typical recurring figure. The Q1, as we mentioned last time, had a number of one time non recurring sort of startup related costs to building a sales force and getting a launch underway early in the year ahead of approval. So that quarter was a little more inflated, if you will, on the SG and A line than I would expect going forward. Speaker 300:27:36So that's why the drop looks as it does. Speaker 900:27:40Very helpful. Thanks for taking the questions and congrats on the progress. Speaker 200:27:45Thanks, Steve. Operator00:27:49Thank you. We go next now to David Bautz at Zacks Small Gap Research. Speaker 1000:27:54Hey, good morning, everybody. Question on the mechanism for how prescriptions are filled. Are they filled on a monthly basis? Is it multiple monthly? And then if you could talk a little bit about how revenue is recognized in relation to when those prescriptions are filled? Speaker 200:28:16Sure. So I mean, I don't think we have intended to disclose kind of the play by play for our patients. I mean, as we mentioned with our current revenue line, it does blend, obviously, both an inventory build as well as revenue recognition for individual patients that are now on commercial therapy. So I don't think at this point we're ready to provide any more details, but certainly we do want we do understand the market's interest in helping them forecast. So as we head into later this year in 2025, we'll try to provide a bit more metrics, which really can help provide some benefit to you all as we think about how the product will grow Speaker 1000:28:54over time. Okay. Thanks for taking the question. Speaker 200:28:59Thank you. Operator00:29:01Thank you. And ladies and gentlemen, it appears we have no further questions this morning. Doctor. Reagan, I'd like to turn things back to you, ma'am, for any closing comments. Speaker 200:29:10Well, thank you so much operator. Thank you everyone for joining the call today and we hope you have an excellent rest of your day. Take care. Operator00:29:18Thank you, Doctor. Reagan. Ladies and gentlemen, again, that does conclude today's X4 Pharmaceuticals 2nd quarter earnings call. Again, thanks so much for joining us everyone and again, we wish you all a great day.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallX4 Pharmaceuticals Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) X4 Pharmaceuticals Earnings HeadlinesBrookline Capital Management Weighs in on XFOR Q3 EarningsMay 6 at 2:11 AM | americanbankingnews.comHC Wainwright Increases X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00May 5 at 1:29 AM | americanbankingnews.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 6, 2025 | Timothy Sykes (Ad)X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comSee More X4 Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email. Email Address About X4 PharmaceuticalsX4 Pharmaceuticals (NASDAQ:XFOR), a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.View X4 Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Upcoming Earnings ARM (5/7/2025)AppLovin (5/7/2025)Fortinet (5/7/2025)MercadoLibre (5/7/2025)Cencora (5/7/2025)Carvana (5/7/2025)Walt Disney (5/7/2025)Emerson Electric (5/7/2025)Johnson Controls International (5/7/2025)Lloyds Banking Group (5/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 11 speakers on the call. Operator00:00:00Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Also, today's call is being recorded. It is now my pleasure to introduce your host, Mr. Operator00:00:29Dan Ferry from LifeSci Advisors. Dan, please go ahead. Speaker 100:00:33Thank you, operator, and good morning, everyone. Thank you for joining us today. Presenting on today's call will be Doctor. Paula Ragan, X4's President and CEO and the company's Chief Financial Officer, Adam Mostafa. Following prepared remarks, we will open up the call to your questions and will be joined by Chief Commercial Officer, Mark Baldry Chief Medical Officer, Doctor. Speaker 100:00:54Christophe Arbitt Engels Chief Operating Officer, Doctor. Mary DiBiase Chief Scientific Officer, Doctor. Art Tavares and Jose Juves, Head of Corporate and Patient Affairs. As a reminder, on today's call, the company will be making forward looking statements regarding regulatory and product development and commercialization plans as well as research activities and financial projections. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Speaker 100:01:26A description of these risks can be found in Exforge's most recent filings with the SEC, including this year's Form 10 ks, which was filed on March 21, 2024, and in the company's Form 10 Q for the 2nd quarter, which is expected to be filed later today. I'll now turn it over to Paula Ragan. Paula? Speaker 200:01:50Thanks so much, Dan, and welcome, everyone. I'll just start by saying what an incredible year we've had so far. Just a few weeks ago, we celebrated the 10th anniversary of X4. When we founded the company a decade ago, a small group of us had a vision to advance our lead asset, an orally active CXCR4 antagonist called maverixaphore to help those with rare diseases who have few to no treatment options. As you saw this past April, we were able to realize this vision receiving U. Speaker 200:02:20S. Approval of maverixophore branded as Zolrembe for the treatment of WIM syndrome, a rare primary immunodeficiency. The U. S. Launch of Zolrembe is now underway and our full commercial team is in place and when patients 12 years and older are now being treated with the only approved therapy targeting the underlying cause of their disease. Speaker 200:02:44Sales guidance on Zolremdi will come at a future point. However, today, I'd like to highlight our strong launch progress. Overall, we've been very pleased with the launch to date. Our launch meeting in early May was a great success where we completed the training and education of our field teams, enabling them to hit the ground running. We got product into our distribution channel very quickly and had our first patients on commercial drug within just a few weeks of product approval. Speaker 200:03:13Coordination with our specialty pharmacy Panther Rx Rare has gone smoothly and we've already received positive feedback on the patient support services provided through our X4 Connect and Nurse Educator programs. And very encouragingly, reimbursement decisions have been coming through quickly with almost all patients currently on therapy receiving reimbursement via prior authorizations and medical exceptions. Our commercial team is fully deployed across the U. S. Calling on key hematologists and immunologists. Speaker 200:03:47To date, there has been limited ability to establish centers of excellence for the WIM community. We knew this going in and therefore are continuing to execute on our disease awareness and education campaigns as well as leveraging our strong relationships with patient advocacy groups. We recently participated in the annual meeting of the Immune Deficiency Foundation or IDF where we engage with physicians, patients and advocates. And members of our team visited with the Jeffrey Modell Foundation in New York just a few weeks ago. Through all of these efforts, we have become better at engaging with the treating physicians, understanding physician and patient questions, and most importantly, building a community of interest around WIM syndrome across the U. Speaker 200:04:32S. We also continue to leverage the positive data from our pivotal Phase III trial in WIM that were published in April in Blood, the Journal of the American Society of Hematology. These and new data from the trial and its open label extension phase were presented at the Annual Meeting of the Clinical Immunological Society or CIS in early May. As we reported at the time, the CIS poster revealed that longer term treatment with ZolremD was associated with durable improvements in neutrophil and lymphocyte counts as well as reductions in annualized infection rates and that no new safety signals have been observed during the OLE phase of the trial with some participants treated for more than 2 years. We also made tremendous progress this past quarter in our development of MAVERICKZIPORE for those with chronic neutropenia, another rare immunodeficiency. Speaker 200:05:29At our investor event in late June, we presented positive interim clinical data from our ongoing Phase 2 clinical trial demonstrating that once daily oral mavrixophore was generally well tolerated and durably increased participants' absolute neutrophil counts or ANC both as a monotherapy and in combination with stable doses of injectable granulocyte colony stimulating factor or G CSF up to as long as 6 months. Importantly, 100% of evaluable participants who had completed the 6 month study as of the mid May cutoff date achieved target ANC increases of greater than 500 cells per microliter at months 36 on once daily MAVERICK-four as a monotherapy and in combination with stable TCSF dosing. In addition, participants on MAVERICKS-four monotherapy achieved mean ANC levels above the lower limit of normal for CN at 3 6 months. And MAVERICK's for monotherapy also durably increased AMC in participants with severe CN defined as ANCs less than 500 cells per microliter at baseline, achieving mean ANCs of 800 to 1000 cells per microliter, which is the A and C range targeted by experts for patients with severe CN. Feedback on these interim results from the physician community has been positive and we were pleased to see the durable impact of MAVERICK-four as a monotherapy and in combination with stable dose G CSF. Speaker 200:07:08These interim data support our strong belief that MAVERICKS-four may be able to address the needs of the CN patients and their physicians, specifically the desire for an oral treatment that does not carry short or long term dose related toxicities described with G CSF use and for an oral treatment that also increases ANC levels and lessens the risk and severity of infections whether used on its own or in combination with G CSF. We're now expecting present the full data from the Phase 2CN trial in November ahead of the American Society of Hematology or ASH meeting. This data set will include results from the group of participants receiving MAVERICK's support and those who are allowed to dose adjust G CSF from baseline. We've been asked what success looks like for these data that will be presented in November. The good news is we already know what success looks like from our WIM Phase 3 study and subsequent approval in the U. Speaker 200:08:08S. In that 52 week study, MAVERICK score meaningfully increased neutrophils and lymphocytes over a sustained period reducing infection rate, duration and severity. From the interim CN Phase II results we shared in June, we saw again that MAVERICK's IV as a monotherapy and in combination with G CSF can increase ANCs to levels expected to reduce infections. In November, we'll be looking to replicate what we saw in June across all participants in the MAVERICKS-four monotherapy and MAV plus stable dose G CSF groups who completed the 6 months of the trial. From the 3rd group, we'll be looking for data that supports physicians' ability to reduce G CSF dosing while on MAVERICK-four and maintain patients' ANCs at clinically meaningful levels. Speaker 200:08:59Finally, we'll be also looking for continued tolerability and safety of MAVERICKS-four as seen in all of our other clinical programs to date. In June, we also announced the initiation of our global pivotal Phase 3 clinical trial branded the FORWARD study evaluating the efficacy, safety and tolerability of oral once daily MAVERICK's 4 with and without stable doses of G CSF in people with congenital acquired primary autoimmune or idiopathic CN who are experiencing recurrent and or serious infections. The 52 week FORWARD trial is a randomized, double blinded, placebo controlled, multicenter study aiming to enroll 150 participants. The clinical operations team is in full swing opening up sites and we are on track to fully enroll the trial in mid-twenty 25. We believe that the interim Phase 2 CN data presented to date strongly support our decision to initiate the Phase 3 trial as well as its design. Speaker 200:10:03Importantly, we believe that the interim results derisk the Phase 3 trial given that the ANC increases seen in CN patients to date mirror those in our successfully completed for a WIM Phase 3 trial, where similar levels of ANC increases led to clinical benefit by reducing the frequency, duration and severity of infections. As we focus our efforts on the FORWARD CAND trial, we are also looking to maximize the global opportunity in WIMS syndrome. We expect an MAA submission to the European Medicines Agency for MAVERICK 4 and WIM syndrome by early 2025, while we also explore additional potential opportunities in geographies where we may be able to efficiently leverage our U. S. FDA approval. Speaker 200:10:50With that, I'll now turn it over to our CFO, Adam Asthafaa to review the Q2 financials. Adam? Speaker 300:10:58Thanks, Paula, and thanks to all of you for being on the call with us today. As we had previously discussed, upon FDA approval of XolRemd, we were awarded a Priority Review Voucher or PRV based on Maverick's 4 rare pediatric disease designation. We monetized this PRV very shortly after receipt and in May, we recognized a gain on the sale to a third party for $105,000,000 in cash. So as of the end of the Q2, ExCoR had $169,500,000 in cash, cash equivalents, restricted cash and short term marketable securities. We believe these funds are sufficient to support our company operations until late 2025. Speaker 300:11:42I want to note that this projected runway does not include potential future Zolram D revenue. For the 3 months ended June 30, we reported revenues of $600,000 and cost of revenue of 0 point $3,000,000 related to the sale of Zolremby. This cost of revenue includes approximately $200,000 of license costs, including sales based royalties and operational milestones capitalized as an intangible asset and amortized over the life of the underlying intellectual property. We would like to note that there was a small amount of inventory stocking at our specialty pharmacy during the quarter and this is reflected in the sales number. Research and development expenses were $20,900,000 for the 2nd quarter compared to $15,600,000 for the comparable period in 2023. Speaker 300:12:37R and D expenses for the Q2 of 2024 included $1,200,000 of non cash expense. Selling, general and administrative expenses were $13,300,000 for the Q2 of 2024. This compares to $10,200,000 for the comparable period in 2023. SG and A expenses for the Q2 also included $1,200,000 of non cash expense. Finally, we reported net income of $90,800,000 for the Q2 of 2024 compared to a net loss of $55,700,000 for the comparable period in 2023. Speaker 300:13:17Note that net income in the current period included the sale of PRV for $105,000,000 as well as a non cash gain of $20,200,000 related to the fair value remeasurement of the company's Class C warrant liability. I'll now turn it back to Paula for some concluding remarks. Speaker 200:13:38As you can see, all of these accomplishments mark a significant step forward for X4, now a fully integrated biopharmaceutical company. As we continue to explore additional uses for and maximize the global potential of MAVERICK's 4 for patients, we look forward to reporting on our sales, regulatory and clinical progress over the coming 6 to 12 months. We'll now open up the call for your questions. Operator? Operator00:14:05Thank you, Doctor. Reagan. We'll go first this morning to Kristin Kluska of Cantor. Speaker 400:14:23Hey, good morning, everybody, and congratulations on reaching 10 years. It's a great milestone and how better to celebrate with a drug approval this year. So first I wanted to ask how you believe physicians are going to measure success differently in a commercial setting versus the clinic for ZolremD? Will it be primarily on patient anecdotes, reports around infections or anything else to consider? Speaker 200:14:50Thanks, Kristen. I'll turn it over to Mark to give some perspectives on what they're hearing from the field. Speaker 500:14:56Yes. We're the launch is well underway, Kristen. And what's exciting is that we're hearing that physicians and patients been waiting for a treatment that targets the underlying cause of the disease. And so now we have the approval of Zolremdi. It's really opening up these conversations and allowing us to help physicians become aware of the disease, recognize the patients in their practice and then think about how they can help these patients with Zolremdi. Speaker 500:15:24We know from the market research that it's really the impact on infections that drives the value of Zolremdi for physicians, for patients and payers. So that's really what I think physicians will be looking for as they get more experience with the product. Speaker 400:15:42Thank you for that. And can you give us a sense of how partnership discussions ex U. S. Are going at this stage? And just curious, your press release noted some ways you're looking to maximize the value of meverx before beyond Wynd syndrome and CN. Speaker 400:15:57So curious as in these conversations this has come up with potential partners about ways that they can also potentially utilize this drug and other indications as well? Speaker 200:16:09Yes. So thanks, Kristen. I mean, when we currently think about the FDA approval, there are certain regions in the world that can leverage that existing approval. So there's some exploration there currently ongoing. Adam can comment more on the more strategic sides of potential collaborations. Speaker 300:16:27Yes. Thanks, Kristen. So certainly there is interest and we have discussions as Paul mentioned ongoing with potential partners. We'll certainly come back and update the market as appropriate if we're going to consummate a transaction. But I think given the recent approval and our recent positive cry neutropenia Phase 2 data, there's only growing interest in this area. Speaker 200:16:51Great. Thank you. Operator00:16:55Thank you. We go next now to Ted Tenthoff at Piper Sandler. Speaker 600:17:00Great. Thank you very much for taking my question. And yes, excited to see some revenues at the company that's and a lot of work has gone to get that first couple of 100 dollars, and I know it will grow from here. My question had to do with sort of characterizing the patients that are on drug. Can you give us a sense for how many patients are on drug? Speaker 600:17:21And anything about sort of the backlog? And if you're not able to give us direct patient numbers, maybe tell us sort of a little bit about the journey of patients that you're seeing as you sort of get them into commercial use of Zolremdi? Thank you. Speaker 200:17:41Thanks so much, Ted. So I think we won't be breaking down any details and continue to report on revenue. But I mean, we're overall extremely pleased with just the cascade of commitment that the company has made and then now we're experiencing the receipt of that commitment in the communities as we head out. But Mark can add some more color and kind of how they're seeing the journey from the diagnosis and education support all the way through patients on drug. Speaker 500:18:05Yes. And I think the first thing to remember, this is an ultra rare disease. And so the key here is to begin to really raise awareness both through the conversations we're having with physicians, our engagement with patient advocacy groups and also through our digital marketing campaigns because that's where we can get extended reach and we've refreshed our disease awareness campaign. We've also launched our branded Zolremdi digital campaigns. So we're really creating this kind of momentum around the conversations. Speaker 500:18:38And the patients as Paula mentioned on the call, all of the patients that were in the open label extension have been prescribed ZIL REMBI here in the U. S. And so from there we're just learning more and more about how the patients have been waiting for a treatment that targets their disease and they're now having those conversations with physicians. Speaker 600:19:01Great. That's really helpful. I appreciate the additional color. Operator00:19:08Thank you. We go next now to RK at H. C. Wainwright. Speaker 700:19:12Thank you. Good morning, Paula and Adam. Congratulations on the 10 years and also the launch. In terms of I know it's early stages of the launch, but when you go and attend these conferences such as the immunodeficiency conference, However, what is it that you're hearing from physicians and patients at this point in terms of getting ready to take to adopt the drug? And also have you learned anything else that needs to be looked at in terms of improving I'm not saying improving, getting that option to a better level from the get go. Speaker 200:20:10Thanks so much, RK. I think we're very pleased with kind of the cascade of thinking and development. And certainly what we're hearing and Mark will add to this is, number 1, they're excited about a targeted therapy and I'll even add the oral targeted therapy. It's been a field of injectable treatments with varying degrees of study and rigor. Our Phase 3 was phenomenally successful showing infection burden reduction across rate severity and duration. Speaker 200:20:39So that is a great story to begin with and a great data set to share. And then in terms of the clinicians, of course, they're all on their own journey even understanding the disease and then learning about the benefits of ZolremD. But I'll turn it over to Mark to add some color to that as well. Speaker 500:20:55Yes, exactly. I think it's really now that we have an approved product, it's really energized physicians to go back and really look in their practice for these patients who before now have really had no treatment available for their disease. And so now we've actually given them a reason to go back, look for these patients, make the diagnosis and then have a conversation with the patient about Zolremdi. Speaker 700:21:19Fantastic. And then for the SCN indication, so between now and if there is an interim analysis for the FORWARD study, is there any other data that will be presented so that we can understand how this program is moving forward? Speaker 200:21:49Sure. So, as we shared today, we'll be giving the full Phase 2 data set in November of this year. So, of course, we were extremely pleased with the data set already, but it was interim. So we've already seen durable responses of the drug as monotherapy and then sustained and durable responses in addition to stable G CSF. So the final puzzle piece is just exploring, in what circumstances G can get reduced. Speaker 200:22:14So that full data set will come in November, which is going to be certainly well timed, just before ASH, we'll be at the ASH meeting to help support the CN community and also get the word further out on our trial enrollment. So it's an excellent timing perspective and then we'll look forward as appropriate to giving updates on how the whole study is going, but certainly that will be a 2025 update. Speaker 700:22:40Perfect. Thank you very much for taking my questions, Paul. Speaker 200:22:45Thanks, RK. Operator00:22:48We'll take our next question now from Lia Can of Brookline Capital Markets. Speaker 800:22:53Good morning. I have a financial question. So Adam, could you help us with the number of fully diluted shares at the end of the quarter, including the prefunded warrants? Speaker 700:23:07Sure. Speaker 300:23:08Thanks. So there's about 167,000,000 basic shares, regular shares outstanding, dollars 33,000,000 prefunded warrants. So $200,000,000 of share equivalents, if you will. And then there are $75,000,000 warrants that are cash only. Those are divided into 2 tranches, $130,000,000 tranche, dollars 145,000,000 tranche. Speaker 300:23:35So overall, dollars 275,000,000 in fully diluted shares. There's some historical warrants you'll see later today in our 10 Q that are significantly out of the money and are typically not included, but that accounts for a small piece. Speaker 800:23:49Thank you so much. Most helpful. Operator00:23:56We go next now to Stephen Willey at Stifel. Speaker 900:24:02Yes, good morning. Thank you for taking the questions. Speaker 500:24:06Could you maybe just talk Speaker 900:24:08a little bit about and again, I understand that it's early, but the kinetics of the reimbursement process, I know the paperwork that is required sometimes for these higher price rare disease drugs can be a somewhat lengthy process. And just curious if you have an early read just based on the limited experience thus far as to what that process might look like from just a timing perspective? Speaker 200:24:39Sure, Steve. I mean, I'll turn it over to Mark. I think classic ultra rare disease typically has barriers that a lot of these insurance companies naturally provide given the magnitude of the drug and its options for patients. But the good news is I think we've had an very experienced team well ahead of this. So I'll turn it over to Mark to give some insights there. Speaker 500:25:00Yes. Thanks, Paul. Hi, Steve. Yes, as Paul mentioned during the call, payers are using their standard methods for new drugs. And so, they're looking at PAs and exceptions process, But these are working quite smoothly and patients have been able to access Oremdi. Speaker 500:25:17Of course, we also have our full suite of patient service programs through our X4 Connect, which is our patient hub. And this ensures that patients are quickly get quick access to the product while we work through the reimbursement. But it's good to see the process working smoothly. Speaker 900:25:39Okay. That's helpful. And maybe a guidance question, not one related to actual sales, but just curious how you're thinking about communicating enrollment progress in the Phase III FORWARD trial going forward? Should we expect updates in conjunction with certain milestones hit like 50%? Or is this just going to be kind of a moving target and we'll hear about it when we hear about it? Speaker 200:26:14Yes. Thanks, Steve. I think we'll always aim to communicate meaningful progress. Of course, we don't want to make any commitments just because it's a 2025 target and it's almost a year away at this point. However, certainly as we get confidence under our belt here, we'll be able to provide some more specifics. Speaker 200:26:33But again, I would say that's a 2025 zone to share. Speaker 900:26:40Okay. And then maybe just another financial question for Adam. SG and A just looks to be down about 25% sequentially, which I guess I wouldn't have been anticipated in the context of undertaking a launch. So can you just remind us if there's anything either unique to the 1 quarter number or this quarter number that impacts that SG and A line item? Thank you. Speaker 300:27:12Sure. Thanks, Steve. Yes, so this second quarter number is probably more representative of a typical recurring figure. The Q1, as we mentioned last time, had a number of one time non recurring sort of startup related costs to building a sales force and getting a launch underway early in the year ahead of approval. So that quarter was a little more inflated, if you will, on the SG and A line than I would expect going forward. Speaker 300:27:36So that's why the drop looks as it does. Speaker 900:27:40Very helpful. Thanks for taking the questions and congrats on the progress. Speaker 200:27:45Thanks, Steve. Operator00:27:49Thank you. We go next now to David Bautz at Zacks Small Gap Research. Speaker 1000:27:54Hey, good morning, everybody. Question on the mechanism for how prescriptions are filled. Are they filled on a monthly basis? Is it multiple monthly? And then if you could talk a little bit about how revenue is recognized in relation to when those prescriptions are filled? Speaker 200:28:16Sure. So I mean, I don't think we have intended to disclose kind of the play by play for our patients. I mean, as we mentioned with our current revenue line, it does blend, obviously, both an inventory build as well as revenue recognition for individual patients that are now on commercial therapy. So I don't think at this point we're ready to provide any more details, but certainly we do want we do understand the market's interest in helping them forecast. So as we head into later this year in 2025, we'll try to provide a bit more metrics, which really can help provide some benefit to you all as we think about how the product will grow Speaker 1000:28:54over time. Okay. Thanks for taking the question. Speaker 200:28:59Thank you. Operator00:29:01Thank you. And ladies and gentlemen, it appears we have no further questions this morning. Doctor. Reagan, I'd like to turn things back to you, ma'am, for any closing comments. Speaker 200:29:10Well, thank you so much operator. Thank you everyone for joining the call today and we hope you have an excellent rest of your day. Take care. Operator00:29:18Thank you, Doctor. Reagan. Ladies and gentlemen, again, that does conclude today's X4 Pharmaceuticals 2nd quarter earnings call. Again, thanks so much for joining us everyone and again, we wish you all a great day.Read morePowered by